Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: a phase I trial.
Wilson
J M
JM
University of Michigan, Ann Arbor.
Engelhardt
J F
JF
Grossman
M
M
Simon
R H
RH
Yang
Y
Y
D017498:Adenovirus E1 Proteins / Q000235:genetics*; D000260:Adenoviruses, Human / Q000235:genetics*; D000328:Adult; D000818:Animals; D001980:Bronchi / Q000473:pathology; D017690:Cell Transplantation; D002478:Cells, Cultured; D002642:Chick Embryo; D002985:Clinical Protocols; D003550:Cystic Fibrosis / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D005260:Female; D017353:Gene Deletion; D015316:Genetic Therapy; D005822:Genetic Vectors; D006168:Guinea Pigs; D006801:Humans; D008168:Lung / Q000473:pathology*; D008253:Macaca mulatta; D008297:Male; D008565:Membrane Proteins / Q000172:deficiency / Q000235:genetics*; D051379:Mice; D008822:Mice, Transgenic; D011993:Recombinant Fusion Proteins; D012306:Risk; D012449:Safety; D014183:Transplantation, Heterologous
D017498:Adenovirus E1 Proteins; C505032:CFTR protein, human; D008565:Membrane Proteins; D011993:Recombinant Fusion Proteins; D019005:Cystic Fibrosis Transmembrane Conductance Regulator